Alain Moussy's guest appearances

Alain Moussy

Empowered Patient Podcast

Le Journal des Biotechs

Daniel Cohen

Nawal Ouzren

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

Andrew Newberg

OwlTail

Alain Moussy is the Co-Founder and CEO of AB Science a clinical-stage company designing and developing novel drugs to address diseases with high unmet medical needs. Masitinib, their drug in development is being investigated in neurological diseases such as amyotrophic lateral sclerosis, Alzheimer's, and multiple sclerosis as well for severe forms of COVID-19 and as an antiviral anti-protease in ambulatory COVID-19 patients. Alain explains, "We have started two such studies in amyotrophic lateral sclerosis (ALS) disease, which is well known across the world, and another one in a rare disease called Mastocytosis, and those two studies are up and running. We have also started a phase 2 in COVID with masitinib after the University of Chicago discovered that masitinib is actually a potent antiviral against the virus, which was actually a surprise for us. Now that we have this data, we are developing masitinib for COVID as an antiviral. And you know, Karen, we need an antiviral along with the vaccine to fight this pandemic." "The development of masitinib in Covid was not anticipated because our drug was not designed to be an antiviral. It's just that the structure of the protease of the virus has a strong affinity with the structure of our compound by chance. The co-crystallizations of the protease of the virus with masitinib, which has been done by the University of Chicago, show that they match." #ABScience #COVID19 #Masitinib #AntiviralDrug #ALS #Alzheimers #MS AB-Science.com Download the transcript here

Alain Moussy is the Co-Founder and CEO of AB Science a clinical-stage company designing and developing novel drugs to address diseases with high unmet medical needs. Masitinib, their drug in development is being investigated in neurological diseases such as amyotrophic lateral sclerosis, Alzheimer's, and multiple sclerosis as well for severe forms of COVID-19 and as an antiviral anti-protease in ambulatory COVID-19 patients. Alain explains, "We have started two such studies in amyotrophic lateral sclerosis (ALS) disease, which is well known across the world, and another one in a rare disease called Mastocytosis, and those two studies are up and running. We have also started a phase 2 in COVID with masitinib after the University of Chicago discovered that masitinib is actually a potent antiviral against the virus, which was actually a surprise for us. Now that we have this data, we are developing masitinib for COVID as an antiviral. And you know, Karen, we need an antiviral along with the vaccine to fight this pandemic." "The development of masitinib in Covid was not anticipated because our drug was not designed to be an antiviral. It's just that the structure of the protease of the virus has a strong affinity with the structure of our compound by chance. The co-crystallizations of the protease of the virus with masitinib, which has been done by the University of Chicago, show that they match." #ABScience #COVID19 #Masitinib #AntiviralDrug #ALS #Alzheimers #MS <a href="http://AB-Science.com" rel="noopener nofollow" target="_blank">AB-Science.com</a> <a href="http://empoweredpatientradio.com/developing-an-oral-antiviral-to-fight-covid-19-and-neurodegenerative-diseases-with-alain-moussy-ab-science-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Developing an Oral Antiviral to Fight COVID-19 and Neurodegenerative Diseases with Alain Moussy AB Science

Alain Moussy, Co-Founder and CEO, AB Science has applied their lead compound Masitinib to target mast cells and macrophage, also known when presenting with CNS as microglia, from the innate immune system to treat Lou Gehrig's disease, multiple sclerosis, Alzheimer's disease, tumors, and pancreatic cancer.  Now AB Science is turning their attention to fighting the cytokine storm in COVID-19 patients by targeting and blocking mast cells and macrophages which are known to contribute to the inflammation. #masitinib #PancreaticCancer #COVID19 #Alzheimers AB-Science.com Download the transcript here

Alain Moussy, Co-Founder and CEO, AB Science has applied their lead compound Masitinib to target mast cells and macrophage, also known when presenting with CNS as microglia, from the innate immune system to treat Lou Gehrig's disease, multiple sclerosis, Alzheimer's disease, tumors, and pancreatic cancer.  Now AB Science is turning their attention to fighting the cytokine storm in COVID-19 patients by targeting and blocking mast cells and macrophages which are known to contribute to the inflammation. #masitinib #PancreaticCancer #COVID19 #Alzheimers <a href="http://ab-science.com" rel="noopener nofollow" target="_blank">AB-Science.com</a> <a href="http://empoweredpatientradio.com/masitinib-targeting-and-blocking-mast-cells-and-macrophages-to-treat-covid-19-with-alain-moussy-ab-science-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Masitinib Targeting and Blocking Mast Cells and Macrophages to Treat COVID-19 with Alain Moussy AB Science

Le Journal des Biotechs du 3 mars 2020Interview de Alain Moussy, directeur général d'AB Science. Le Journal des Biotechs donne la parole à Alain Moussy, directeur général d'AB Science qui revient sur les dernières annonces faites par la société dont le cours flambe actuellement : +112% sur les six derniers mois.

Le Journal des Biotechs du 3 mars 2020 Interview de Alain Moussy, directeur général d'AB Science. Le Journal des Biotechs donne la parole à Alain Moussy, directeur général d'AB Science qui revient sur les dernières annonces faites par la société dont le cours flambe actuellement : +112% sur les six derniers mois.